Navigation

The Company
Our Science
Our Medicine
- Our Medicine
- Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
- Overview
- Patient Advocacy
Contact Us

cache

Home cache

Next Post
Previous Post

cache

David Dornan, PhD

January 1, 2020 / Uncategorized

Like this post!

Share the Post

About the Author

Related Posts

Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

cache

Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021

Andrew Kwon, PhD

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa

Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa

New Drug Trial Gives Hope for Treatment-Resistant Epilepsy

Comments

Comments are closed.

Next Post
Previous Post

Recent Articles

David Dornan, PhD
Baiteng Zhao, PhD
Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database
A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts

Home
Pipeline
Patients
Contact
Careers

Terms & Conditions
Privacy